Mature dendritic cells differentiated in the presence of interferon-β and interleukin-3 prime functional antigen-specific CD8+ T cells

Clinical and Experimental Immunology

Volumn 139, Issue 3, 2005, Pages 468-475

  Renneson, J ^a,b   Salio, M ^a   Mazouz, N ^b   Goldman, M ^b   Marchant, Arnaud ^b,c   Cerundolo, Vincenzo ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b ERASME HOSPITAL   (Belgium)

^c Laboratory of Experimental Neurology   (Belgium)

Author keywords

Cancer; Cytotoxic T cells; Dendritic cells; Vaccines

Indexed keywords

BETA INTERFERON; CD40 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; MELAN A; MELAN A [26-35]; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; LYMPHOCYTE COUNT; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

CANCER VACCINES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-3; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; LYMPHOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 14744302052     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02700.x     Document Type: Article

References (25)

1. Yu Z, Restifo NP. Cancer vaccines: progress reveals new complexities. J Clin Invest 2002; 110:289-94.
2. Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113:1515-25.
3. Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 2004; 5:7-10.
4. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80.
5. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
6. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-18.
7. Buelens C, Bartholome EJ, Amraoui Z et al. Interleukin-3 and Interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood 2002; 99:993-8.
8. Santini SM, Di Pucchio T, Lapenta C, Parlato S, Logozzi M, Belardelli F. A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells. Stem Cells 2003; 21:357-62.
9. + lymphocytes as compared with nonprofessional APC. J Immunol 2001; 167:1188-97.
10. Rometo P, Gervois N, Schneider J et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997; 159:2366-74.
11. Altman JD, Moss PA, Goulder PJ et al Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-6.
12. Buelens C, Bartholome EJ, Amraoui Z et al. Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood 2002; 99:993-8.
13. + lymphocytes as compared with nonprofessional APC. J Immunol 2001; 167:1188-97.
14. Stift A, Sachet M, Yagubian R et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 2004; 10:2944-53.
15. Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63:2127-33.
16. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190:1669-78
17. Salio M, Palmowski MJ, Atzberger A, Hermans IF, Cerundolo V. CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. J Exp Med 2004; 199:567-79.
18. Salio M, Cella M, Vermi W et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003; 33:1052-62.
19. Buelens C, Bartholome EJ, Amraoui Z et al. Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood 2002; 99:993-8.
20. + T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4:1009-15.
21. Kalady MF, Onaitis MW, Emani S, Abdel-Wahab Z, Tyler DS, Pruitt SK. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. J Surg Res 2004; 116:24-31.
22. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002; 195:335-41.
23. + T cell response. J Immunol 2003; 170:5195-202.
24. Mohty M, Vialle-Castellano A, Nunes JA, Isnardon D, Olive D, Gaugler B. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J Immunol 2003; 171:3385-93.
25. + T cell responses against human tumor antigens. J Immunol 2004; 172:5363-70.